{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:07:59Z","timestamp":1764259679127},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.3816\/clm.2009.n.051","type":"journal-article","created":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T00:27:43Z","timestamp":1245198463000},"page":"E1-E4","source":"Crossref","is-referenced-by-count":5,"title":["Multiple Significant Bortezomib-Related Toxicities in One Patient: Case Report and Literature Review"],"prefix":"10.3816","volume":"9","author":[{"given":"Jeanette M.","family":"Waller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Moretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin B.","family":"Knopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.n.051_bib1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1159\/000099284","article-title":"Management of multiple myeloma with bortezomib: experts review the data and debate the issues","volume":"70","author":"Dicato","year":"2006","journal-title":"Oncology"},{"key":"10.3816\/CLM.2009.n.051_bib2","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.n.051_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1367-5931(02)00343-5","article-title":"Preclinical and clinical evaluation of the proteasome inhibitor PS-341 for the treatment of cancer","volume":"6","author":"Adams","year":"2002","journal-title":"Curr Opin Chem Biol"},{"key":"10.3816\/CLM.2009.n.051_bib4","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.051_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.051_bib6","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.051_bib7","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood-2005-02-0691","article-title":"Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. The SUMMIT Investigators","volume":"106","author":"Richardson","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.051_bib8","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.051_bib9","series-title":"Velcade (bortezomib) for Injection [US package insert]","year":"2003"},{"key":"10.3816\/CLM.2009.n.051_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/MEG.0b013e32811ebffe","article-title":"Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor","volume":"19","author":"Perfetti","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.3816\/CLM.2009.n.051_bib11","first-page":"1655","article-title":"Treatment of relapsed or refractory Waldenstr\u00f6m's macroglobulinemia with bortezomib","volume":"90","author":"Dimopoulos","year":"2005","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.n.051_bib12","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1158\/1078-0432.CCR-04-0422","article-title":"Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors","volume":"10","author":"Shah","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.n.051_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1634\/theoncologist.11-1-51","article-title":"A Practical Update on the use of bortezomib in the management of multiple myeloma","volume":"11","author":"San Miguel","year":"2006","journal-title":"Oncologist"},{"key":"10.3816\/CLM.2009.n.051_bib14","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.051_bib15","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cncr.22921","article-title":"Neurotoxcity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature","volume":"110","author":"Badros","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.n.051_bib16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2006.06.030","article-title":"Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma","volume":"55","author":"Wu","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2009.n.051_bib17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1365-2133.2007.08073.x","article-title":"Bortezomib-associated cutaneous vasculitis","volume":"157","author":"Garcia-Noavarro","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.3816\/CLM.2009.n.051_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2437.x","article-title":"Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines","volume":"76","author":"Min","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2009.n.051_bib19","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMicm041166","article-title":"Images in clinical Medicine. Bortezomib-induced skin lesions","volume":"352","author":"Agterof","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.051_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000094689","article-title":"Bortezomib-induced skin lesion","volume":"116","author":"Ozcan","year":"2006","journal-title":"Acta Haematol"},{"key":"10.3816\/CLM.2009.n.051_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00277-006-0227-9","article-title":"Late onset of bortezomib-associated cutaneous reaction following herpes zoster","volume":"86","author":"Varettoni","year":"2007","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2009.n.051_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2141.2005.05636.x","article-title":"Bortezomib-induced Sweet syndrome","volume":"131","author":"Knoops","year":"2005","journal-title":"Br J Hematol"},{"key":"10.3816\/CLM.2009.n.051_bib23","first-page":"ECR43","article-title":"Bortezomib-induced Sweet's syndrome","volume":"90","author":"Van Regenmortel","year":"2005","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.n.051_bib24","first-page":"ECR44","article-title":"Skin lesions induced by bortezomib","volume":"90","author":"Pour","year":"2005","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.n.051_bib25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2141.2006.06201.x","article-title":"Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib; a possible surrogate marker of response?","volume":"134","author":"Gerecitano","year":"2006","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T19:52:20Z","timestamp":1545162740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011702037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S1557919011702037"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.n.051","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}